July 25, 2016
Press Release
GreenPeptide Co., Ltd.
President & CEO: Kenichi Nagai(Code: 4594, TSE Mothers)
Inquiries: Teruhiko Sakai, Director/CFO
T E L : 0 3 - 5 8 4 0 - 7 6 9 7Announcement Concerning Development of Immunoassay
Procedures Outsourced to GreenPeptide
GreenPeptide Co. , Ltd. (President & CEO Kenichi Nagai; GreenPeptide) wishes toannounce that it has concluded an agreement with Bristol-Myers Squibb K.K.
(Shinjuku-ku, Tokyo; President & CEO Davide Piras; BMS) regarding the outsourced
development of immunoassay procedures for use in research concerning the efficacy ofOrencia®** (Generic name: Abatacept, genetically recombinant), a rheumatoid arthritis
agent manufactured and marketed by BMS, as well as regarding the performance of theassay procedure in such research.
■Background to outsourcing agreement
In recent years, in order to demonstrate the clinical usefulness of cancer peptide
vaccines being developed by GreenPeptide, we have developed immunoassay methods
using Luminex® 100/200TM system *. The techniques developed for research on cancer
immunotherapies will be applied in the development of the immunoassay procedures foruse in the research on the rheumatoid arthritis therapy. The high evaluation by BMS ofthese techniques, our experience with them and the setup for their performance led to theconclusion of the current agreement.
GreenPeptide will actively continue to utilize its proprietary technologies, and work
forward to develop pharmaceutical products.
■ Effect on results
In the past, GreenPeptide has been entrusted with the development and performance ofassay techniques for pharmaceutical products and antibodies by other companies, andthese sales were booked resulting as few percent addition. The sales arising from theconclusion of this agreement will account for a few percent of sales in the year to March1

2017 and the effect on results will be minimal.
This agreement will not result in out-licensing.
It will not affect the progress of the company’s existing pipeline.

*Luminex® 100/200™ System
This is an assay system developed by the US company Luminex Corporation, which cansimultaneously assay multiple micro-volume samples using various types of micro-beads
based on flow cytometry principles. It has been licensed to GreenPeptide by Luminex.
**OrenciaOrencia is a genetically recombinant version of a soluble fusion protein composing theextracellular domain of human cytotoxic T- lymphocyte-antigen-4 (CTLA-4) and the Fc
domain of human IgG1developed by BMS. It is a biopharmaceutical product that has animproving action on the signs and symptoms of rheumatoid arthritis, physical functions
and quality of life by suppressing T-cell activation by binding specifically with CD80
ｓin December 2005 and is now marketed in over 50 countries worldwide. In Japan, it
was approved as an intravenous infusion in July 2010, then as a subcutaneous injection
syringe in June 2013 and as a subcutaneous auto-injector formulation in February 2016.

About GreenPeptide
GreenPeptide is a drug discovery venture company engaged in the research anddevelopment of cancer immunotherapies that make use of the body’s immune system tofight cancer. There are hopes that cancer immunotherapies will be the 4th therapy whensurgery, radiotherapy and chemotherapy have failed.
GreenPeptide is actively developing cancer immunotherapy candidates with the aim thatthey become innovative new cancer treatments.

2